Outlook Therapeutics (OTLK) announced the Scottish Medicines Consortium, SMC, acceptance of LYTENAVA for use within NHS Scotland for the treatment of wet age-related macular degeneration. LYTENAVA is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and Healthcare products Regulatory Agency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Launches LYTENAVA in Europe
- Outlook Therapeutics announces commercial launch of LYTENAVA in Germany, UK
- Outlook Therapeutics Announces New Stock and Warrant Offering
- Outlook Therapeutics 9.3M share Spot Secondary priced at $1.40
- Outlook Therapeutics Reports Improved Financials Amid Challenges